These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 23352637)

  • 1. Rituximab maintenance therapy until progression after rituximab and chemotherapy induction in patients with follicular lymphoma.
    Yared J; Kimball A; Baer MR; Bahrain H; Auerbach M
    Clin Lymphoma Myeloma Leuk; 2013 Jun; 13(3):253-7. PubMed ID: 23352637
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial.
    Coiffier B; Osmanov EA; Hong X; Scheliga A; Mayer J; Offner F; Rule S; Teixeira A; Walewski J; de Vos S; Crump M; Shpilberg O; Esseltine DL; Zhu E; Enny C; Theocharous P; van de Velde H; Elsayed YA; Zinzani PL;
    Lancet Oncol; 2011 Aug; 12(8):773-84. PubMed ID: 21724462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of the introduction of rituximab in first-line follicular lymphoma: a retrospective study of 247 unselected patients referred to a single institution with a long-term follow-up.
    Nicolas-Virelizier E; Ségura-Ferlay C; Ghesquières H; Chassagne-Clément C; Gargi T; Biron P; Belhabri A; Rey P; Faurie P; Chabaud S; Sebban C
    Hematol Oncol; 2015 Mar; 33(1):1-8. PubMed ID: 24496668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Maintenance with rituximab is safe and not associated with severe or uncommon infections in patients with follicular lymphoma: results from the phase IIIb MAXIMA study.
    Witzens-Harig M; Foá R; Di Rocco A; van Hazel G; Chamone DF; Rowe JM; Arcaini L; Poddubnaya I; Ho AD; Ivanova V; Vranovsky A; Thurley D; Oertel S
    Ann Hematol; 2014 Oct; 93(10):1717-24. PubMed ID: 24824768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes of Treatment in Slovene Follicular Lymphoma Patients.
    Južnič Šetina T; Borštnar S; Jezeršek Novaković B
    Clin Lymphoma Myeloma Leuk; 2015 Oct; 15(10):586-91. PubMed ID: 26423702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of bortezomib in combination with rituximab, cyclophosphamide and prednisone with or without doxorubicin followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma.
    Craig M; Hanna WT; Cabanillas F; Chen CS; Esseltine DL; Neuwirth R; O'Connor OA
    Br J Haematol; 2014 Sep; 166(6):920-8. PubMed ID: 25039282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.
    Salles G; Seymour JF; Offner F; López-Guillermo A; Belada D; Xerri L; Feugier P; Bouabdallah R; Catalano JV; Brice P; Caballero D; Haioun C; Pedersen LM; Delmer A; Simpson D; Leppa S; Soubeyran P; Hagenbeek A; Casasnovas O; Intragumtornchai T; Fermé C; da Silva MG; Sebban C; Lister A; Estell JA; Milone G; Sonet A; Mendila M; Coiffier B; Tilly H
    Lancet; 2011 Jan; 377(9759):42-51. PubMed ID: 21176949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial participants.
    Trotman J; Fournier M; Lamy T; Seymour JF; Sonet A; Janikova A; Shpilberg O; Gyan E; Tilly H; Estell J; Forsyth C; Decaudin D; Fabiani B; Gabarre J; Salles B; Van Den Neste E; Canioni D; Garin E; Fulham M; Vander Borght T; Salles G
    J Clin Oncol; 2011 Aug; 29(23):3194-200. PubMed ID: 21747087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab purging and/or maintenance in patients undergoing autologous transplantation for relapsed follicular lymphoma: a prospective randomized trial from the lymphoma working party of the European group for blood and marrow transplantation.
    Pettengell R; Schmitz N; Gisselbrecht C; Smith G; Patton WN; Metzner B; Caballero D; Tilly H; Walewski JA; Bence-Bruckler I; To B; Geisler CH; Schots R; Kimby E; Taverna CJ; Kozák T; Dreger P; Uddin R; Ruiz de Elvira C; Goldstone AH
    J Clin Oncol; 2013 May; 31(13):1624-30. PubMed ID: 23547078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab-based pre-emptive treatment of molecular relapse in follicular and mantle cell lymphoma.
    Ferrero S; Monitillo L; Mantoan B; Barbero D; Genuardi E; Barbiero S; Bernocco E; Caracciolo D; Ruella M; Drandi D; Zanni M; Renna F; Lobetti Bodoni C; Gueli A; Passera R; Musto P; Boccadoro M; Tarella C; Ladetto M
    Ann Hematol; 2013 Nov; 92(11):1503-11. PubMed ID: 23737092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study.
    Davies A; Merli F; Mihaljevic B; Siritanaratkul N; Solal-Céligny P; Barrett M; Berge C; Bittner B; Boehnke A; McIntyre C; Macdonald D
    Lancet Oncol; 2014 Mar; 15(3):343-52. PubMed ID: 24521993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma--a randomized phase II trial of the Minnie Pearl Cancer Research Network.
    Hainsworth JD; Litchy S; Shaffer DW; Lackey VL; Grimaldi M; Greco FA
    J Clin Oncol; 2005 Feb; 23(6):1088-95. PubMed ID: 15657401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fludarabine-mitoxantrone-rituximab regimen in untreated intermediate/high-risk follicular non-Hodgkin's lymphoma: experience on 142 patients.
    Zinzani PL; Pellegrini C; Broccoli A; Casadei B; Argnani L; Pileri S
    Am J Hematol; 2013 Nov; 88(11):E273-6. PubMed ID: 23843267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic rituximab in multifocal primary cutaneous follicle centre lymphoma.
    Quéreux G; Brocard A; Peuvrel L; Nguyen JM; Knol AC; Dréno B
    Acta Derm Venereol; 2011 Sep; 91(5):562-7. PubMed ID: 21629975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial.
    Ardeshna KM; Qian W; Smith P; Braganca N; Lowry L; Patrick P; Warden J; Stevens L; Pocock CF; Miall F; Cunningham D; Davies J; Jack A; Stephens R; Walewski J; Ferhanoglu B; Bradstock K; Linch DC
    Lancet Oncol; 2014 Apr; 15(4):424-35. PubMed ID: 24602760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Follicular non-Hodgkin's lymphoma: correlation between histology, pathophysiology, cytogenetic, prognostic factors, treatment, survival.
    Găman AM
    Rom J Morphol Embryol; 2013; 54(1):71-6. PubMed ID: 23529311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of anthracycline at first-line compared to alkylating agents or nucleoside analogs improves the outcome of salvage treatments after relapse in follicular lymphoma The REFOLL study by the Fondazione Italiana Linfomi.
    Rossi G; Marcheselli L; Dondi A; Bottelli C; Tucci A; Luminari S; Arcaini L; Merli M; Pulsoni A; Boccomini C; Puccini B; Micheletti M; Martinelli G; Rossi A; Zilioli VR; Bozzoli V; Balzarotti M; Bolis S; Cabras MG; Federico M
    Am J Hematol; 2015 Jan; 90(1):56-61. PubMed ID: 25327841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab plus short-duration chemotherapy as first-line treatment for follicular non-Hodgkin's lymphoma: a phase II trial of the minnie pearl cancer research network.
    Hainsworth JD; Litchy S; Morrissey LH; Andrews MB; Grimaldi M; McCarty M; Greco FA
    J Clin Oncol; 2005 Mar; 23(7):1500-6. PubMed ID: 15632411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cost-effectiveness analysis of maintenance therapy with rituximab in patients with follicular lymphoma responding to induction therapy at the first line].
    Castro Gómez AJ; López-Guillermo A; Rueda Domínguez A; Salar A; Varela Moreno C; Rubio-Terrés C
    Rev Esp Salud Publica; 2012; 86(2):163-76. PubMed ID: 22991059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Obinutuzumab for the First-Line Treatment of Follicular Lymphoma.
    Marcus R; Davies A; Ando K; Klapper W; Opat S; Owen C; Phillips E; Sangha R; Schlag R; Seymour JF; Townsend W; Trněný M; Wenger M; Fingerle-Rowson G; Rufibach K; Moore T; Herold M; Hiddemann W
    N Engl J Med; 2017 Oct; 377(14):1331-1344. PubMed ID: 28976863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.